Inveresk Research Report issue

For profit Phase 2
Founded: Cary NC United States (1999)
Status: Acquired by Charles River (2004)

Organization Overview

First Clinical Trial
2002
NCT00036517
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2003

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Inveresk Research Group, Incorporated

Active Ingredients

Drugs in Phase 2 Trials (2)

forodesine (2 trials)

phy906 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 2)

Diarrhea (Phase 2)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2